Replies to post #280441 on Avid Bioservices Inc (CDMO)

[biopharm]

CJ thanks! Dec 7th hours away...and hopefully Dr. Jedd Wolchok can shed some more light on how the non-responders will not be left behind.

12-7-16/WED 10am: JEDD D. WOLCHOK, MD/PhD(Mem. Sloan Kettering)
Lecture: ”Combination Checkpoint Blockade" (free to public)
Location: The Wistar Institute, Philadelphia (Jedd D. Wolchock: Chief of Melanoma & Immunotherapeutics Service, MSKCC)
https://www.wistar.org/events/2016/12/combination-checkpoint-blockade

...We don’t know if Dr. Wolchok will mention Peregrine/Bavi in his talk (North40000/Eb0783/Wook will let us know!), but RECALL that on 11-14-16, Dr. Wolchok’s MSKCC Lab Team, jointly with PPHM Scientists, presented a poster at SITC’16 on Triple Combo Rad+Bavi+aPD1 vs. Melanoma:
...11-14-16/SITC’16: Dr. Jedd Wolchok states, “Based on these study results, we believe that the targeting of PS is having meaningful activity within the tumor microenvironment in the B16 melanoma model. It appears that this activity creates a more immune active environment in which other treatments, including radiation, are able to have a greater anti-tumor impact.”
#199/SITC’16/11-11-16(MSK+PPHM): Phosphatidylserine Targeting Antibody in Combination with Checkpoint Blockade & Tumor Radiation Therapy Promotes Anti-Cancer Activity in Mouse Melanoma” See: http://tinyurl.com/js3fca4

[Protector]

cjgaddy, thanks for this reminder.

Mem.Sloan’s Jedd.Wolchok Video/July2014: “Immunotherapy for Metastatic Melanoma, PD-1 Clinical Trials”… Dr. Wolchok (1:42), “We will not rest until every patient can have a durable response.” cyberspaceandtime.com/kvWeW8Zt0sU.video (1:49)

If Wolchok (Memorial Sloan Kettering) puts his DETERMINATION where is mouth is then to achieve DURABLE he will need BAVITUXIMAB.

Blocking immune system suppression by binding to PS (the ligand) or PS-Receptors is INSUFFICIENT because if the immune system is not activated then the Auto Immune System's learning feature remains inactive TOO.

Assuming that Dr. Wolchok means NO RELAPSE when he uses the word DURABLE he will need to activate the Auto Immune System and allow it to LEARN the problem at hand and create tailor made anti-bodies for future fast detection and combat if a same problem comes back. And hence he needs to activate the immune system.

Bavituximab's Fc-Gamma (receptors on MDSC, M2 Macrophages and immature dendric cells) binding starts this immune stimulatory action (IL-12 and TNF-Alpha secretion) after the PS binding itself blocked imuno-suppression (no IL-10 and TGF-Beta secretion).

What Wolchok says at 1:10 in the video, today we know it is a short-term effect and PD-1 patients do relapse around 24-36 months approx. It was stated as two years but we know that will not be an exact figure and be a patient dependant range (source was posted on here).

This is where Dr. Brekken's research and the mice dying from old age comes in.